Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReDACKD
NCT05113641Completed
- Start
- Aug 2023
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Randomised, open-label trial in chronic kidney disease (CKD) and metabolic acidosis (2 arms). Primary endpoints: Randomization to preliminary eligible ratio at 12 months, Weekly recruitment rate at 12 months and 2 more. Started Aug 2023; status: completed.
02
Conditions
chronic kidney disease (CKD)metabolic acidosis
Beyond the preview
Go deeper on NCT05113641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113641.